Efficacy and Safety of Topiramate as Monotherapy in Treatment of Partial Epilepsy in Children: A Randomized Controlled Trial
Keywords:Topiramate (TPM); monotherapy; partial epilepsy; efficacy
Background: Partial epilepsy is more common among children.
Objective: The aim of the study was to compare the efficacy and safety of Topiramate (TPM) to previously recommended drug Carbamazepine (CBZ) in the treatment of partial epilepsy.
Methodology: This randomized controlled trial was conducted in outpatient department of Pediatric Neurology at National Institute of Neurosciences and Hospital (NINS&H), Dhaka, Bangladesh during the period of July 2017 to December 2017. Children with the age group of 0 to 18 years who were diagnosed as newly onset partial epilepsy were randomized into study group (TPM) and control group (CBZ). The efficacy and safety of TPM was evaluated after 6 months of treatment.
Results: A total number of 50 children were recruited for this study. The primary outcome was assessed in 50 children by measuring frequency of seizure before and after treatment. Seizure frequency decrease significantly after treatment with both drugs where TPM group was 5.21±2.96 to 1.80±0.94 and CBZ group was 6.83±4.88 to 1.80±1.0/month respectively (p <0.001).
Conclusion: Topiramate is effective and safe in the treatment of partial epilepsy in children.
Journal of National Institute of Neurosciences Bangladesh, January 2022; 8(1):14-18
How to Cite
Copyright (c) 2022 Most Shameem Ara Begum, Banita Mistry, Narayan Saha, Shyamal Sarker, Dipa Saha, Mahua Chandra, Nazmul Haque
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright on any research article in the Journal of National Institute of Neurosciences Bangladesh is retained by the author(s).
The authors grant the National Institute of Neurosciences Bangladesh a license to publish the article and identify itself as the original publisher.
Articles in the Journal of National Institute of Neurosciences Bangladesh are Open Access articles published under the Creative Commons CC BY-NC License (https://creativecommons.org/licenses/by-nc/4.0/)
This license permits use, distribution and reproduction in any medium, provided the original work is properly cited, and it is not used for commercial purposes.